<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00920257</url>
  </required_header>
  <id_info>
    <org_study_id>112689</org_study_id>
    <nct_id>NCT00920257</nct_id>
  </id_info>
  <brief_title>A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795</brief_title>
  <official_title>A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2141795 in Subjects With Solid Tumors or Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a first time in human, Phase I, open-label, dose-escalation study of the oral&#xD;
      AKT inhibitor GSK2141795 in subjects with solid tumors or lymphomas.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 16, 2009</start_date>
  <completion_date type="Actual">April 17, 2013</completion_date>
  <primary_completion_date type="Actual">April 17, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the recommended Phase II dose and schedule of GSK214179 using the following information: safety and tolerability, pharmacokinetic (single and repeat dose administration) and pharmacodynamic data</measure>
    <time_frame>Continune until disease progression or consent withdrawn</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>â€¢ To explore the clinical efficacy of GSK2141795 in subjects with solid tumor malignancies or lymphomas</measure>
    <time_frame>Continune until disease progression or consent withdrawn</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the metabolite profile of oral GSK2141795 after repeat dose administration in subjects with solid tumor malignancies or lymphoma</measure>
    <time_frame>Continune until disease progression or consent withdrawn</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>GSK2141795</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral GSK214179 given daily to patients with cancer. Groups of approximately three patients will receive GSK2141795 at increasing doses until a maximum tolerated dose is identified.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2141795</intervention_name>
    <description>GSK2141795 is an oral AKT inhibitor.</description>
    <arm_group_label>GSK2141795</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  Male or female, 18 years or older.&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of solid tumor malignancy or&#xD;
             lymphoma that is not responsive to standard therapies or for which there is no&#xD;
             approved or curative therapy. Subjects with malignancies related to human&#xD;
             immunodeficiency virus (HIV) or solid organ transplant are excluded.&#xD;
&#xD;
          -  Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology Group&#xD;
             (ECOG) scale.&#xD;
&#xD;
          -  Able to swallow and retain oral medication.&#xD;
&#xD;
          -  Fasting serum glucose &lt;126 mg/dL.&#xD;
&#xD;
          -  Male subjects with a female partner of childbearing potential must have had a prior&#xD;
             vasectomy or agree to use adequate contraception from the time of the first dose of&#xD;
             GSK2141795 until three months after the last dose of GSK2141795.&#xD;
&#xD;
          -  A female subject is eligible to participate if she is of non-child bearing potential,&#xD;
             or of child-bearing potential and willing to use adequate birth control&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  (Part 2 only - endometrial) Histologically or cytologically confirmed diagnosis of&#xD;
             relapsed or metastatic endometrial cancer.&#xD;
&#xD;
          -  (Part 2 only - endometrial) No more than two prior cytotoxic chemotherapy regimens in&#xD;
             the relapsed or metastatic setting. Targeted agents like bevacizumab are not&#xD;
             considered cytotoxic chemotherapy for the purposes of this study&#xD;
&#xD;
          -  (Part 2 only, breast) Histologically or cytologically confirmed diagnosis of locally&#xD;
             advanced or metastatic breast cancer.&#xD;
&#xD;
          -  (Part 2 only, breast) No more than three prior cytotoxic chemotherapy regimens in the&#xD;
             metastatic setting. Targeted agents like lapatinib, bevacizumab, and trastuzumab are&#xD;
             not considered cytotoxic chemotherapy for the purposes of this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy, radiotherapy, or immunotherapy within 28 days (or 42 days for prior&#xD;
             nitrosoureas or mitomycin C) prior to the first dose of GSK2141795. Chemotherapy&#xD;
             regimens given continuously or on a weekly basis with limited potential for delayed&#xD;
             toxicity are permitted with approval of a GSK Medical Monitor if dosing of that&#xD;
             chemotherapy is terminated at least 14 days prior to the first dose of GSK2141795.&#xD;
&#xD;
          -  Use of an investigational anti-cancer drug within 28 days or five half-lives,&#xD;
             whichever is longer, preceding the first dose of GSK2141795.&#xD;
&#xD;
          -  Current use of a prohibited medication or requires any of these medications during&#xD;
             treatment with GSK2141795.&#xD;
&#xD;
          -  Current use of anticoagulants at therapeutic levels within seven days prior to the&#xD;
             first dose of GSK2141795, including warfarin, low molecular weight heparin and direct&#xD;
             thrombin inhibitors. Low dose (prophylactic) anticoagulants such as warfarin, low&#xD;
             molecular weight heparin, selective Factor Xa inhibitors or direct thrombin inhibitors&#xD;
             are permitted provided that subject's PT and PTT meet entry criteria.&#xD;
&#xD;
          -  Presence of active gastrointestinal disease or other condition that could affect&#xD;
             gastrointestinal absorption (e.g. malabsorption syndrome) or predispose a subject to&#xD;
             gastrointestinal ulceration.&#xD;
&#xD;
          -  Current use of any anti-platelet agent (e.g. dipyridamole, clopidogrel) other than&#xD;
             aspirin (81 mg daily).&#xD;
&#xD;
          -  Any major surgery within the last four weeks of screening.&#xD;
&#xD;
          -  Unresolved toxicity (except alopecia) greater than or equal to Grade 2 from previous&#xD;
             anti-cancer therapy unless agreed to by a GSK Medical Monitor and the investigator,&#xD;
             and where a GSK Medical Monitor and the investigator consider that the ongoing&#xD;
             toxicity will not introduce additional risk factors and will not interfere with the&#xD;
             study procedures.&#xD;
&#xD;
          -  Previously diagnosed diabetes mellitus (type 1 or 2).&#xD;
&#xD;
          -  Current use of oral corticosteroids, with the exception of inhaled or topical&#xD;
             corticosteroids.&#xD;
&#xD;
          -  History of an allogeneic stem cell transplant. Subjects with a history of an&#xD;
             autologous stem cell transplant are NOT excluded.&#xD;
&#xD;
          -  Any serious or unstable pre-existing medical, psychiatric, or other condition&#xD;
             (including lab abnormalities) that could interfere with subject safety or with&#xD;
             obtaining informed consent.&#xD;
&#xD;
          -  Symptomatic or untreated CNS metastases or leptomeningeal involvement. Subjects who&#xD;
             were previously treated for these conditions, and are asymptomatic without&#xD;
             anti-epileptic medications or steroids for at least 2 months are eligible. Subjects&#xD;
             with primary brain tumor are excluded.&#xD;
&#xD;
          -  Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated&#xD;
             respiratory, hepatic, renal, or cardiac disease).&#xD;
&#xD;
          -  QTc interval greater than or equal to 470 msecs.&#xD;
&#xD;
          -  Other clinically significant ECG abnormalities including 2nd degree (type II) or 3rd&#xD;
             degree atrioventricular (AV) block.&#xD;
&#xD;
          -  History of myocardial infarction, acute coronary syndromes (including unstable&#xD;
             angina), coronary angioplasty, or stenting or bypass grafting within the past 6&#xD;
             months.&#xD;
&#xD;
          -  Class III or IV heart failure as defined by the New York Heart Association (NYHA)&#xD;
             functional classification system.&#xD;
&#xD;
          -  Pregnant or Lactating females.&#xD;
&#xD;
          -  History of HIV infection; history of hepatitis B or C (subject with evidence of&#xD;
             cleared hepatitis B are eligible)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>June 12, 2009</study_first_submitted>
  <study_first_submitted_qc>June 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2009</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oncology</keyword>
  <keyword>breast cancer</keyword>
  <keyword>AKT inhibitor</keyword>
  <keyword>first time in human</keyword>
  <keyword>lymphoma</keyword>
  <keyword>endometrial cancer</keyword>
  <keyword>GSK2141795</keyword>
  <keyword>solid tumors</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

